Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 130 matching trials from the live ClinicalTrials.gov search.
Conditions
Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
Interventions
Cixutumumab, Laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Conditions
Metastatic Uveal Melanoma
Interventions
Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma
Interventions
carboplatin, paclitaxel, bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Vorinostat
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
3
States / cities
New York, New York • Nashville, Tennessee
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
IFA, 6MHP, GM-CSF
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Metastatic Melanoma
Interventions
sunitinib malate, temozolomide
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Intraocular Melanoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7, Unresectable Melanoma
Interventions
Bevacizumab, Ipilimumab, Laboratory Biomarker Analysis, Nab-paclitaxel, Pharmacological Study
Biological · Other · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
13
States / cities
San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 10 more
Conditions
Uveal Melanoma, Hepatic Metastases
Interventions
SIR-Spheres® Yttrium 90, ipilimumab, nivolumab
Device · Drug
Lead sponsor
David Minor, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Neoadjuvant and Adjuvant Checkpoint Blockade

NCT02519322
Conditions
Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Acral Lentiginous Melanoma AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Relatlimab, Therapeutic Conventional Surgery
Biological · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Interventions
IOV-3001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Denver, Colorado • Chapel Hill, North Carolina • Nashville, Tennessee
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
pyrazoloacridine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Interventions
IDE196, Binimetinib, Crizotinib
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
Autologous Dendritic Cells (DC), Fludarabine, Autologous Lymphocyte Infusion (ALI)
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Uveal Neoplasms, Choroid Neoplasms, Iris Neoplasms
Interventions
Fine needle aspiration biopsy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Metastatic, Uveal Melanoma
Interventions
75mg selumetinib, placebo, Dacarbazine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more
Conditions
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Uveal Melanoma, Metastatic
Interventions
Dexamethasone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
La Jolla, California
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage IV Non-Small Cell Lung Cancer, Stage IV Skin Melanoma, Melanoma of Unknown Primary
Interventions
Pembrolizumab, Stereotactic Radiosurgery
Biological · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Interventions
Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)
Combination Product
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Palo Alto, California • Tampa, Florida • Durham, North Carolina + 2 more
Conditions
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Interventions
cyclophosphamide, lenalidomide, sunitinib malate
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
lomustine, temozolomide, thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
New York, New York
Conditions
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Melanoma, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IIA Cutaneous Melanoma AJCC v6 and v7, Stage IIA Uveal Melanoma AJCC v7, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIB Uveal Melanoma AJCC v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo, Sargramostim, Tyrosinase Peptide
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
148
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more